Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Schilder, Louise ^a   Nurmohamed, S Azam ^a   Ter Wee, Pieter M ^a   Paauw, Nanne J ^a   Girbes, Armand R J ^a   Beishuizen, Albertus ^a   Beelen, Robert H J ^a   Groeneveld, A B Johan ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute kidney injury; Biocompatibility; Citrate; Complement activation; Critically ill patients; Elastase; Heparin; MPO; Neutrophils; Renal replacement therapy

Indexed keywords

CITRATE TRISODIUM; COMPLEMENT COMPONENT C5A; ELASTASE; HEPARIN; MYELOPEROXIDASE; POTASSIUM;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BIOCOMPATIBILITY; BLOOD SAMPLING; COMPLEMENT ACTIVATION; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL PATIENT; DEGRANULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERVOLEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL; NEUTROPHIL DEGRANULATION; RENAL REPLACEMENT THERAPY; RESPIRATORY DISTRESS; ULTRAFILTRATION;

ADULT; AGED; ANTICOAGULANTS; CITRIC ACID; COMPLEMENT C5A; CRITICAL CARE; CRITICAL ILLNESS; DRUG SYNERGISM; FEMALE; HEMOFILTRATION; HEPARIN; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84892461403     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-19     Document Type: Article

References (23)

1. Acute renal failure in critically ill patients: a multinational, multicenter study. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C, for the beginning and ending supportive therapy for the kidney (BEST Kidney) investigators, JAMA 2005 294 813 818 10.1001/jama.294.7.813 16106006 (Pubitemid 41175724)
2. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Palsson R, Niles JL, Kidney Int 1999 55 1991 1997 10.1046/j.1523-1755.1999.00444.x 10231464 (Pubitemid 29197989)
3. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study. Nurmohamed SA, Vervloet MG, Girbes AR, Ter Wee PM, Groeneveld AB, Blood Purif 2007 25 316 323 10.1159/000107045 17700015 (Pubitemid 47450565)
4. Citrate anticoagulation for continuous venovenous hemofiltration. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF, Crit Care Med 2009 37 545 552 10.1097/CCM.0b013e3181953c5e 19114912
5. Biocompatibility of hemodialysis membranes. Cheung AK, J Am Soc Nephrol 1990 1 150 161 2104259
6. Patient characteristics rather than the type of dialyser predict the variability of endothelial derived surface molecules in chronic haemodialysis patients. Grooteman MP, Gritters M, Wauters IM, Schalkwijk CG, Stam F, Twisk J, Ter Wee PM, Nubé MJ, Nephrol Dial Transplant 2005 20 2751 2758 10.1093/ndt/gfi126 16188898 (Pubitemid 41672276)
7. Effect of anticoagulation regimens on handling of interleukin-6 and -8 during continuous venovenous hemofiltration in critically ill patients with acute kidney injury. Schilder L, Nurmohamed SA, Ter Wee PM, Girbes AR, Beishuizen A, Paauw NJ, Beelen RH, Groeneveld AB, Cytokine 2012 60 601 607 10.1016/j.cyto.2012.08.015 23006672
8. The effects of high molecular weight- and low molecular weight-heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes. Léculier C, Couprie N, Adeleine P, Leitienne P, Francina A, Richard M, Thromb Hemost 1993 69 519 531 (Pubitemid 23106438)
9. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophils degranulation. Böhler J, Schollmeyer P, Dressel B, Dobos G, Hörl WH, J Am Soc Nephrol 1996 7 234 241 8785392 (Pubitemid 26092473)
10. Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Bos JC, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nubé MJ, Nephrol Dial Transplant 1997 12 1387 1393 10.1093/ndt/12.7.1387 9249774 (Pubitemid 27353028)
11. Heparins and blood polymorphonuclear stimulation in haemodialysis: an expansion of the biocompatibility concept. Leitienne P, Fouque D, Rigal D, Adeleine P, Trzeciak M-C, Laville M, Nephrol Dial Transplant 2000 15 1631 1637 10.1093/ndt/15.10.1631 11007833
12. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Gritters M, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Scheffer PG, Teerlink T, Schalkwijk CG, Spreeuwenberg M, Nubé MJ, Nephrol Dial Transplant 2006 21 153 159 10.1093/ndt/gfi069 16144857 (Pubitemid 43057124)
13. Reduction in platelet activation by citrate anticoagulation does not prevent intradialytic hemodynamic instability. Gritters M, Borgdorff P, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Tangelder GJ, Nubé MJ, Nephron Clin Pract 2007 106 9 c16 10.1159/000100496 17347579 (Pubitemid 46701508)
14. Myeloperoxidase concentrations in EDTA-plasma of healthy subjects are discordant with concentrations in heparin-plasma and serum. Scheffer PG, van der Zwan LP, Schindhelm RK, Vermue HP, Teerlink T, Clin Biochem 2009 42 1490 1492 10.1016/j.clinbiochem.2009.06.004 19524564
15. Regional citrate anticoagulation reduces polymorphonucelar cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Tiranathanagul K, Jearnsujitwimol O, Susantitaphong P, Kijkriengkraikul N, Leelahavanichkul A, Srisawat N, Praditpornsilpa K, Eiam-Ong S, Ther Apher Dial 2011 15 556 564 10.1111/j.1744-9987.2011.00996.x 22107692
16. Factors influencing local and systemic levels of plasma myeloperoxidase in ST-segment elevation acute myocardial infarction. Marshall CJ, Nallaratnam M, Mocatta T, Smyth D, Richards M, Elliott JM, Blake J, Winterbourn CC, Kettle AL, McClean DR, Am J Cardiol 2010 106 316 322 10.1016/j.amjcard.2010.03.028 20643239
17. High-volume haemofiltration in human septic shock. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P, Intensive Care Med 2001 27 978 986 10.1007/s001340100963 11497156 (Pubitemid 32662478)
18. Mediators of complement-independent granulocyte activation during haemodialysis: role of calcium, prostaglandins and leukotrienes. Böhler J, Donauer J, Birmelin M, Schollmeyer PJ, Hörl WH, Nephrol Dial Transplant 1993 8 1359 1365 8159305 (Pubitemid 24038071)
19. The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C, J Nephrol 2004 17 819 825 15593057 (Pubitemid 41158302)
20. Beta2 integrins are required for neutrophil degranulation induced by hemodialysis membranes. Cheung AK, Parker CJ, Hohnholt M, Kidney Int 1993 43 649 660 10.1038/ki.1993.94 8455364 (Pubitemid 23071949)
21. Plasma levels of myeloperoxidase and elastase are differentially regulated by hemodialysis membranes and anticoagulants. Ono K, Ueki K, Inose K, Tsuchida A, Yano S, Nojima Y, Res Commun Mol Pathol Pharmacol 2000 108 341 349 11958287 (Pubitemid 34563344)
22. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. Borawski J, Am J Kidney Dis 2006 47 37 41 10.1053/j.ajkd.2005.10.001 16377383 (Pubitemid 41828264)
23. Plasma elastase alpha1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators of fatal sepsis. Nuijens JH, Abbink JJ, Wachtfogel YT, Colman RW, Eerenberg AJ, Dors D, Kamp AJ, Strack van Schijndel RJ, Thijjs LG, Hack CE, J Lab Clin Med 1992 119 159 168 1740629